Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Nuance Acquires Sino Health in a Deal Worth at Least $32 Million

publication date: Jan 6, 2022

Shanghai Nuance Pharma acquired Sino Health Pharmaceutical together with two of its subsidiaries in a deal worth "multi hundred million RMB" -- at least $32 million. Sino Health has three commercial stage products and a candidate under NDA review in China, plus a sales force of over 100 people. Nuance expects the acquisition to increase its presence in emergency care and retail sales, while also adding to its sales and distribution network. Nuance offers high-quality products and services that address unmet China medical needs. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital